AbbVie Hepatitis C Drug Cures 97% in Transplant Patients Study
This article is for subscribers only.
AbbVie Inc.’s hepatitis C treatment cured 97 percent of patients who had received a liver transplant, a study showed today, potentially adding a valuable option for a group that’s highly vulnerable to the disease.
In a mid-stage study of 34 patients, 33 were cured of the virus after 24 weeks of treatment with AbbVie’s experimental cocktail of ombitasvir, ritonavir, dasabuvir, ABT-450, and ribavirin, an antiviral drug used to supplement hepatitis C treatments. The study was published today in the New England Journal of Medicine.